bcg + neisvac-c + pediacel + infanrix + prevenar-13 + menitorix + priorix + rotarix

This entry refers to a specific combination vaccine regimen evaluated in a University of Oxford pilot study (NCT01535638) titled 'Impact of BCG on MenC Vaccine Immunogenicity.' The regimen investigates the non-specific immunomodulatory effects of the Bacillus Calmette–Guérin (BCG) vaccine on the immune response to other routine childhood vaccines when administered at birth or at three months of age. The components of this regimen follow the United Kingdom childhood immunization schedule and include: **BCG** (live attenuated *Mycobacterium bovis*); **NeisVac-C** (a serogroup C meningococcal conjugate vaccine); **Pediacel** (a 5-in-1 DTaP-IPV-Hib vaccine); **Infanrix** (a DTaP vaccine); **Prevenar-13** (a 13-valent pneumococcal conjugate vaccine); **Menitorix** (a Hib-MenC conjugate vaccine); **Priorix** (a Measles-Mumps-Rubella vaccine); and **Rotarix** (a live attenuated oral rotavirus vaccine). The study's primary focus is to determine if the early administration of BCG enhances the immunogenicity of the meningococcal C (MenC) vaccine and other co-administered antigens through heterologous immune stimulation.

Brand names

NeisVac-CPediacelInfanrixPrevenar-13Prevenar13Prevenar 13MenitorixPriorixRotarix

Other names

BCGBacillus Calmette-Guérin vaccineBCG, NeisVac-C, Pediacel, Infanrix, Prevenar-13, Menitorix, Priorix, Rotarix